BG108038A - Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes - Google Patents

Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes

Info

Publication number: BG108038A
Authority: BG; Bulgaria
Prior art keywords: alkyl; inhibitors; nicotinamide; derivatives useful; biaryl derivatives
Prior art date: 2001-01-31

Application number

BG108038A

Other languages

Bulgarian (bg)

English (en)

Inventor

Robert J. Chambers

Thomas V. Magee

Anthony Marfat

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-01-31

Filing date

2003-07-28

Publication date

2004-07-30

2003-07-28 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2004-07-30 Publication of BG108038A publication Critical patent/BG108038A/xx

Links

239000003112 inhibitor Substances 0.000 title abstract 2
101100296719 Caenorhabditis elegans pde-4 gene Proteins 0.000 title 1
108010044467 Isoenzymes Proteins 0.000 title 1
229960003966 nicotinamide Drugs 0.000 title 1
235000005152 nicotinamide Nutrition 0.000 title 1
239000011570 nicotinamide Substances 0.000 title 1
DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 title 1
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
206010006458 Bronchitis chronic Diseases 0.000 abstract 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 abstract 1
101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 abstract 1
230000004913 activation Effects 0.000 abstract 1
208000006673 asthma Diseases 0.000 abstract 1
206010006451 bronchitis Diseases 0.000 abstract 1
208000007451 chronic bronchitis Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
210000003979 eosinophil Anatomy 0.000 abstract 1
230000001105 regulatory effect Effects 0.000 abstract 1
125000003003 spiro group Chemical group 0.000 abstract 1
125000001424 substituent group Chemical group 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Oncology (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Communicable Diseases (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Dermatology (AREA)
Psychiatry (AREA)
Tropical Medicine & Parasitology (AREA)
Psychology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Biotechnology (AREA)
Addiction (AREA)
Hospice & Palliative Care (AREA)

BG108038A 2001-01-31 2003-07-28 Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes BG108038A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US26549201P	2001-01-31	2001-01-31
PCT/IB2001/002341 WO2002060875A1 (fr)	2001-01-31	2001-12-06	Derives de biaryl nicotinamide utiles comme inhibiteurs d'isozymes de pde4

Publications (1)

Publication Number	Publication Date
BG108038A true BG108038A (en)	2004-07-30

Family

ID=23010671

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG108038A BG108038A (en)	2001-01-31	2003-07-28	Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes

Country Status (25)

Country	Link
US (2)	US6649633B2 (fr)
EP (1)	EP1355884A1 (fr)
JP (1)	JP2004520386A (fr)
KR (1)	KR20030074761A (fr)
CN (1)	CN1518542A (fr)
BG (1)	BG108038A (fr)
BR (1)	BR0116852A (fr)
CA (1)	CA2436535A1 (fr)
CR (1)	CR7025A (fr)
CZ (1)	CZ20031895A3 (fr)
EA (1)	EA200300621A1 (fr)
EC (2)	ECSP034709A (fr)
EE (1)	EE200300360A (fr)
HU (1)	HUP0400637A2 (fr)
IL (1)	IL156413A0 (fr)
IS (1)	IS6846A (fr)
MA (1)	MA26983A1 (fr)
MX (1)	MXPA03006887A (fr)
NO (1)	NO20033397L (fr)
NZ (1)	NZ526453A (fr)
OA (1)	OA12540A (fr)
PL (1)	PL364135A1 (fr)
SK (1)	SK8792003A3 (fr)
WO (1)	WO2002060875A1 (fr)
ZA (1)	ZA200304894B (fr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030055026A1 (en)	2001-04-17	2003-03-20	Dey L.P.	Formoterol/steroid bronchodilating compositions and methods of use thereof
EP1389468A4 (fr) *	2001-05-23	2007-01-10	Tanabe Seiyaku Co	Compositions favorisant la gu rison d'une fracture osseuse
CN1537018A (zh) *	2001-05-23	2004-10-13	田边制药株式会社	一种用于软骨疾病再生治疗的组合物
AU2002367730A1 (en) *	2002-02-26	2003-09-09	Stephen L. Schlesinger	Use of leukotriene receptor antagonist for treatment of scarring
EP1424101A3 (fr) *	2002-11-29	2004-08-18	NOZAKI, Masako	Utilisation d'un antagoniste du leucotriène c4/d4 pour la préparation d'un médicament pour le traitement ou la prévention d'une inflammation ou septicémie du cerveau
AU2003300076C1 (en)	2002-12-30	2010-03-04	Angiotech International Ag	Drug delivery from rapid gelling polymer composition
US7153824B2 (en) *	2003-04-01	2006-12-26	Applied Research Systems Ars Holding N.V.	Inhibitors of phosphodiesterases in infertility
GB0309781D0 (en) *	2003-04-29	2003-06-04	Glaxo Group Ltd	Compounds
TWI359675B (en)	2003-07-10	2012-03-11	Dey L P	Bronchodilating β-agonist compositions
US7132435B2 (en) *	2003-07-25	2006-11-07	Pfizer Inc.	Compounds
GB0317484D0 (en) *	2003-07-25	2003-08-27	Pfizer Ltd	Nicotinamide derivatives useful as pde4 inhibitors
US7153870B2 (en)	2003-07-25	2006-12-26	Pfizer Inc.	Nicotinamide derivatives useful as PDE4 inhibitors
US20050020587A1 (en) *	2003-07-25	2005-01-27	Pfizer Inc	Nicotinamide derivatives useful as PDE4 inhibitors
GB0317516D0 (en) *	2003-07-25	2003-08-27	Pfizer Ltd	Nicotinamide derivatives useful as PDE4 inhibitors
GB0317482D0 (en) *	2003-07-25	2003-08-27	Pfizer Ltd	Nicotinamide derivatives useful as pde4 inhibitors
GB0317498D0 (en) *	2003-07-25	2003-08-27	Pfizer Ltd	Compounds
US7534894B2 (en)	2003-09-25	2009-05-19	Wyeth	Biphenyloxy-acids
US20050154006A1 (en) *	2004-01-09	2005-07-14	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions based on a scopineester and nicotinamide derivatives
WO2006073413A1 (fr) *	2004-02-20	2006-07-13	The Board Of Trustees Of The University Of Illinois	Reduction de la pression sanguine dans l'hypertension dependant du sel
WO2005087236A1 (fr) *	2004-03-11	2005-09-22	Glaxo Group Limited	Nouveaux antagonistes du recepteur de l'acetylcholine muscarinique m3
JP4793692B2 (ja)	2004-04-26	2011-10-12	小野薬品工業株式会社	新規なｂｌｔ２介在性疾患、ｂｌｔ２結合剤および化合物
US7704522B2 (en) *	2004-09-08	2010-04-27	Clyde Morgan	Topical medicament
US8597947B2 (en)	2004-12-29	2013-12-03	Hadasit Medical Research Services & Development Limited	Undifferentiated stem cell culture systems
EP1844136B1 (fr)	2004-12-29	2014-08-27	Hadasit Medical Research Services And Development Ltd.	Systemes de culture de cellules souches
EP2258358A3 (fr)	2005-08-26	2011-09-07	Braincells, Inc.	Neurogenèse avec un inhibiteur de l'acetylcholinestérase
EP2275095A3 (fr)	2005-08-26	2011-08-17	Braincells, Inc.	Neurogenese par modulation des recepteurs muscariniques
EP1940389A2 (fr)	2005-10-21	2008-07-09	Braincells, Inc.	Modulation de la neurogenese par inhibition de la pde
AU2006308889A1 (en)	2005-10-31	2007-05-10	Braincells, Inc.	GABA receptor mediated modulation of neurogenesis
TWI385169B (zh)	2005-10-31	2013-02-11	Eisai R&D Man Co Ltd	經雜環取代之吡啶衍生物及含有彼之抗真菌劑
JP2009514969A (ja)	2005-11-09	2009-04-09	コンビナトアールエックスインコーポレーティッド	医学的状態を治療するための方法、組成物、およびキット
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
EP2382975A3 (fr)	2006-05-09	2012-02-29	Braincells, Inc.	Neurogénèse par modulation d'angiotensine
JP2009536667A (ja)	2006-05-09	2009-10-15	ブレインセルス，インコーポレイティド	５ｈｔ受容体介在性の神経新生
AU2007292848A1 (en)	2006-09-08	2008-03-13	Braincells, Inc.	Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
EP2117538A1 (fr)	2007-01-24	2009-11-18	Glaxo Group Limited	Compositions pharmaceutiques contenant du 2-méthoxy-5- (5-trifluorométhyl-tétrazol-i-yl-benzyl) - (2s-phényl-pipéridin-3s-yl-)
EP2147094B2 (fr)	2007-04-18	2018-02-21	Hadasit Medical Research Services & Development Limited	Cellules de l'épithélium pigmentaire de la rétine dérivées de cellules souches
US8513287B2 (en)	2007-12-27	2013-08-20	Eisai R&D Management Co., Ltd.	Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
WO2010099217A1 (fr)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
KR102110469B1 (ko)	2009-05-12	2020-05-14	코닌클리케 필립스 엔.브이.	악성의 호르몬 민감성 전립선 암에 대한 마커로서의 포스포디에스테라제 4ｄ7
ES2700877T3 (es)	2009-05-12	2019-02-19	Koninklijke Philips Nv	Fosfodiesterasa 4D7 como marcador de cáncer de próstata
WO2011028689A1 (fr)	2009-09-01	2011-03-10	Catabasis Pharmaceuticals, Inc.	Conjugués acides gras niacine et leurs utilisations
USRE46608E1 (en)	2009-09-01	2017-11-14	Catabasis Pharmaceuticals, Inc.	Fatty acid niacin conjugates and their uses
US20110082210A1 (en) *	2009-10-05	2011-04-07	Milne Jill C	Fatty acid fibrate derivatives and their uses
WO2013106547A1 (fr)	2012-01-10	2013-07-18	President And Fellows Of Harvard College	Composés promoteurs de réplication des cellules bêta et leurs procédés d'utilisation
EP3013796B9 (fr) *	2013-06-27	2020-07-01	LG Chem, Ltd.	Dérivés de biaryle en tant qu'agonistes de gpr120
JP6293266B2 (ja) *	2013-09-17	2018-03-14	ヴェクタスバイオシステムズリミテッド	高血圧及び／又は線維症の処置用組成物
CA2972575A1 (fr)	2014-12-30	2016-07-07	Cell Cure Neurosciences Ltd.	Populations de cellules de l'epr et leurs procedes de production
EP3916085A1 (fr)	2014-12-30	2021-12-01	Cell Cure Neurosciences Ltd.	Évaluation de populations de cellules épithéliales pigmentaires rétiniennes
WO2017017686A1 (fr)	2015-07-29	2017-02-02	Hadasit Medical Research Services And Development Ltd.	Production à grande échelle de cellules de l'épithélium pigmentaire rétinien
US11066642B2 (en)	2015-08-05	2021-07-20	Cell Cure Neurosciences Ltd	Preparation of retinal pigment epithelium cells
EP3331995A1 (fr)	2015-08-05	2018-06-13	Cell Cure Neurosciences Ltd.	Préparation de photorécepteurs pour le traitement de maladies rétiniennes
JP6987769B2 (ja)	2015-10-26	2022-01-05	セルキュアニューロサイエンシズリミテッド	網膜色素上皮細胞の調製法
US9725406B1 (en)	2016-10-13	2017-08-08	Resolvex Pharmaceuticals Inc.	Substituted hydroxystilbenes and their therapeutic applications
CN110520139A (zh)	2017-02-08	2019-11-29	哈达西特医疗研究服务和开发有限公司	用于治疗视网膜疾病的感光细胞
WO2018170494A1 (fr)	2017-03-16	2018-09-20	Bio Time, Inc.	Procédés de mesure d'effets thérapeutiques de traitements de maladies rétiniennes
WO2019130061A2 (fr)	2017-12-29	2019-07-04	Cell Cure Neurosciences Ltd.	Compositions de cellules d'épithélium pigmentaire rétinien
US12522587B2 (en)	2018-05-04	2026-01-13	Remedy Plan, Inc.	Cancer treatments targeting cancer stem cells
CA3112135A1 (fr)	2018-09-20	2020-03-26	Yeda Research And Development Co. Ltd.	Methodes de traitement de la sclerose laterale amyotrophique
EP4055008A1 (fr)	2019-11-06	2022-09-14	Remedy Plan, Inc.	Traitements anticancéreux ciblant des cellules souches cancéreuses
US11116737B1 (en)	2020-04-10	2021-09-14	University Of Georgia Research Foundation, Inc.	Methods of using probenecid for treatment of coronavirus infections
CN111888349B (zh) *	2020-07-29	2021-10-22	温州医科大学附属第二医院、温州医科大学附属育英儿童医院	印楝素在制备促进缺血超长随意皮瓣存活药物的作用
EP4351334A1 (fr)	2021-06-09	2024-04-17	Lineage Cell Therapeutics, Inc.	Procédés et compositions pour le traitement de maladies et d'affections rétiniennes
JP2024527986A (ja)	2021-07-28	2024-07-26	リネージセルセラピューティクスインコーポレイテッド	網膜色素上皮細胞の増殖
EP4514949A1 (fr)	2022-04-25	2025-03-05	Hadasit Medical Research Services&Development Ltd.	Procédés et compositions pour le traitement de la perte de vision

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2140772A5 (en)	1971-06-07	1973-01-19	Aries Robert	Phenoxynicotinoylaminophenols - analgesics tranquillisers antipyretics, anti-inflammatories and antirheumatics
US4270946A (en) *	1979-10-01	1981-06-02	Stauffer Chemical Company	N-Aryl,2-phenoxy nicotinamide compounds and the herbicidal use thereof
US4692185A (en) *	1986-01-13	1987-09-08	Stauffer Chemical Company	N-(ortho-substituted) benzyl, 3-trifluoromethylphenoxy nicotinamides as herbicides
US4861891A (en) *	1988-08-31	1989-08-29	Pfizer Inc.	Antidepressant N-substituted nicotinamide compounds
ATE174343T1 (de)	1991-02-27	1998-12-15	Lacer Sa	Antihypertensive n-(alpha-substituiertes pyridyl)-carbonyldipeptide
DE4200323A1 (de)	1992-01-09	1993-07-15	Bayer Ag	Herbizide und pflanzennematizide mittel auf basis von mercaptonicotinsaeurederivaten
US5552438A (en)	1992-04-02	1996-09-03	Smithkline Beecham Corporation	Compounds useful for treating allergic and inflammatory diseases
PT710109E (pt)	1993-06-18	2005-01-31	Smithkline Beecham Corp	Metodo para identificar um inibidor de pde iv
JP3406689B2 (ja)	1994-03-15	2003-05-12	株式会社大塚製薬工場	ナフチリジン及びピリドピラジン誘導体
US5618027A (en) *	1994-07-20	1997-04-08	Nevrekar; Venkatesh R.	Gate valve
WO1996019990A1 (fr)	1994-12-23	1996-07-04	Smithkline Beecham Corporation	Monomeres 4,4-(disubstitues)cyclohexan-1-carboxylate et composes correspondants
TW429148B (en) *	1995-10-27	2001-04-11	Pfizer	Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases
GB9622386D0 (en)	1996-10-28	1997-01-08	Sandoz Ltd	Organic compounds
US5922557A (en)	1997-01-09	1999-07-13	Merck & Co., Inc.	System for stably expressing a high-affinity camp phosphodiesterase and use thereof
AU738037B2 (en)	1997-04-04	2001-09-06	Pfizer Products Inc.	Nicotinamide derivatives
GB9715584D0 (en) *	1997-07-23	1997-10-01	Eisai Co Ltd	Compounds
UA67753C2 (uk)	1997-10-10	2004-07-15	Смітклайн Бічам Корпорейшн	Спосіб отримання заміщених 4-феніл-4-ціанциклогексанових кислот
AR015966A1 (es)	1997-10-17	2001-05-30	Smithkline Beecham Corp	Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
AR015190A1 (es)	1997-10-23	2001-04-18	Smithkline Beecham Corp	Un polimorfo cristalino de 1,3-diciclopropilmetil-8-aminoxantina, procedimiento para su preparacion, composiciones farmaceuticas que lo contienen y su usopara la manufactura de un medicamento
CZ20022410A3 (cs) *	2000-01-31	2003-08-13	Pfizer Products Inc.	Benzoanelované heterocyklylové deriváty nikotinamidu užitečné jako selektivní inhibitory isozymů PDE4
CZ20022413A3 (cs) *	2000-01-31	2003-08-13	Pfizer Products Inc.	Pyrimidinkarboxamidy užitečné jako inhibitory isozymů PDE4

2001
- 2001-12-06 EE EEP200300360A patent/EE200300360A/xx unknown
- 2001-12-06 NZ NZ526453A patent/NZ526453A/en unknown
- 2001-12-06 PL PL01364135A patent/PL364135A1/xx not_active Application Discontinuation
- 2001-12-06 JP JP2002561026A patent/JP2004520386A/ja active Pending
- 2001-12-06 CA CA002436535A patent/CA2436535A1/fr not_active Abandoned
- 2001-12-06 IL IL15641301A patent/IL156413A0/xx unknown
- 2001-12-06 CN CNA018230717A patent/CN1518542A/zh active Pending
- 2001-12-06 KR KR10-2003-7010074A patent/KR20030074761A/ko not_active Ceased
- 2001-12-06 MX MXPA03006887A patent/MXPA03006887A/es not_active Application Discontinuation
- 2001-12-06 CZ CZ20031895A patent/CZ20031895A3/cs unknown
- 2001-12-06 EA EA200300621A patent/EA200300621A1/ru unknown
- 2001-12-06 SK SK879-2003A patent/SK8792003A3/sk not_active Application Discontinuation
- 2001-12-06 HU HU0400637A patent/HUP0400637A2/hu unknown
- 2001-12-06 EP EP01273556A patent/EP1355884A1/fr not_active Withdrawn
- 2001-12-06 BR BR0116852-5A patent/BR0116852A/pt not_active IP Right Cessation
- 2001-12-06 OA OA1200300175A patent/OA12540A/en unknown
- 2001-12-06 WO PCT/IB2001/002341 patent/WO2002060875A1/fr not_active Ceased
2002
- 2002-01-31 US US10/062,813 patent/US6649633B2/en not_active Expired - Fee Related
2003
- 2003-06-16 IS IS6846A patent/IS6846A/is unknown
- 2003-06-24 ZA ZA200304894A patent/ZA200304894B/en unknown
- 2003-07-02 US US10/613,988 patent/US6953810B2/en not_active Expired - Fee Related
- 2003-07-17 CR CR7025A patent/CR7025A/es not_active Application Discontinuation
- 2003-07-21 MA MA27241A patent/MA26983A1/fr unknown
- 2003-07-28 BG BG108038A patent/BG108038A/xx unknown
- 2003-07-30 NO NO20033397A patent/NO20033397L/no not_active Application Discontinuation
- 2003-07-31 EC EC2003004709A patent/ECSP034709A/es unknown
- 2003-07-31 EC EC2003004710A patent/ECSP034710A/es unknown

Also Published As

Publication number	Publication date
US20020193612A1 (en)	2002-12-19
OA12540A (en)	2006-06-05
MXPA03006887A (es)	2003-11-13
HUP0400637A2 (hu)	2004-06-28
CN1518542A (zh)	2004-08-04
PL364135A1 (en)	2004-12-13
ECSP034709A (es)	2003-09-24
EA200300621A1 (ru)	2003-12-25
MA26983A1 (fr)	2004-12-20
KR20030074761A (ko)	2003-09-19
US20040048903A1 (en)	2004-03-11
US6649633B2 (en)	2003-11-18
BR0116852A (pt)	2004-02-25
ECSP034710A (es)	2003-09-24
CZ20031895A3 (cs)	2004-08-18
US6953810B2 (en)	2005-10-11
NZ526453A (en)	2005-01-28
IS6846A (is)	2003-06-16
EP1355884A1 (fr)	2003-10-29
WO2002060875A1 (fr)	2002-08-08
CR7025A (es)	2003-11-25
SK8792003A3 (en)	2004-09-08
EE200300360A (et)	2003-12-15
NO20033397D0 (no)	2003-07-30
CA2436535A1 (fr)	2002-08-08
IL156413A0 (en)	2004-01-04
NO20033397L (no)	2003-09-19
JP2004520386A (ja)	2004-07-08
WO2002060875A8 (fr)	2003-07-31
ZA200304894B (en)	2004-06-24

Publication	Publication Date	Title
BG108038A (en)	2004-07-30	Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes
BG108039A (en)	2004-07-30	Thiazolyl-, oxazolyl-, pyrrolyl- and amidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes
BG107960A (bg)	2004-10-29	Етерни производни използвани като инхибитори на pde4 изозими
AR041009A1 (es)	2005-04-27	Compuestos heterociclicos nitrogenados que presentan actividad inhibitoria contra la integrasa del vih
US5760066A (en)	1998-06-02	Compounds and methods for inhibiting hyper-proliferative cell growth
AP2002002589A0 (en)	2002-09-30	Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of PDE4 isozymes.
NO20074641L (no)	2007-11-01	1-Acetic Acid-Indole Derivatives with PGD2 Antagonist Activity
CY1111083T1 (el)	2015-06-11	Παραγωγα νικοτιναμιδιου χρησιμα ως αναστολεις της p38
ATE458483T1 (de)	2010-03-15	Selektive pyrimidin-a2b-antagonistenverbindungen, ihre synthese und verwendung
HK1038865A1 (zh)	2002-04-04	RAS-法呢基转移酶抑制物与硫丁基醚-7-β-环糊精或2-羟基丙基-β-环糊精的复合物及方法
WO2007071632A3 (fr)	2007-08-30	Derives de pyridinyl-quinazoline et leur utilisation medicale
MXPA05013349A (es)	2006-03-09	Derivados de 2-amino-pirimidina como inhibidores de quinasa raf.
DE60033964D1 (de)	2007-04-26	Phenoxypropanolamin-derivate, ihre herstellung und therapeutische verwendung
McNamara et al.	1990	Potent inhibition of thymidylate synthase by two series of nonclassical quinazolines
YU67703A (sh)	2006-08-17	Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju poremećaja kretanja
TWI264287B (en)	2006-10-21	N-heteroaryl nicotinamide derivatives
MX2007003872A (es)	2007-06-07	Nuevos derivados bis-azaindolicos, preparacion y su uso farmaceutico de los mismos como inhibidores de cinasas.
IL157594A0 (en)	2004-03-28	Carbamate compounds for use in preventing or treating anxiety disorders
DK1412332T3 (da)	2005-05-30	Quinolinderivater og anvendelse deraf som antitumormidler
MX2008001778A (es)	2008-04-07	Combinacion de un agente hipnotico y un compuesto de bis arilo y heteroarilo sustituido y aplicacion terapeutica de la misma.
ATE259359T1 (de)	2004-02-15	Benzoxazol-derivate zur verwendung als integrin- inhibitoren
TW200630095A (en)	2006-09-01	Pharmaceutical compounds
EP0243972A3 (fr)	1989-03-22	Pyridine cyclopropanecarboximides fongicides
AU2661800A (en)	2000-08-01	Azadioxacycloalkenes and their use for combating harmful fungi and animal pests
ATE217868T1 (de)	2002-06-15	Iminooxybenzylverbindungen und ihre verwendung zur bekämpfung von tierischen schädlingen und schadpilzen